ABCB1 and cancer: From a translational perspective, steering the evolutionary dynamics of ABCB1 acquired resistance through the inhibition of metabolism or ECM may represent a novel therapeutic approach for ABCB1-mediated acquired resistance in HGSOC patients as well as for all ABCB1-driven MDR cancers.